In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...
A combination of eribulin (Halaven) and pembrolizumab (Keytruda) offered promising results in patients with metastatic soft tissue sarcomas that were sensitive to immune checkpoint inhibition (ICI), a ...
Asianet Newsable on MSN
Why did IOVA stock gain pre-market today?
The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results